Newsbytes
  • India
  • Business
  • World
  • Politics
  • Sports
  • Technology
  • Entertainment
  • Auto
  • Lifestyle
  • Inspirational
  • Career
  • Bengaluru
  • Delhi
  • Mumbai
  • Videos
  • Visual Stories
  • Reviews
  • Phone Reviews
  • Fitness Bands Reviews
  • Speakers Reviews
  • Find Cricket Statistics
Hindi
More
In the news
Heatwave
Char Dham Yatra
Gyanvapi Mosque
Newsbytes
Hindi
Newsbytes
User Placeholder

Hi,

Logout


India
Business
World
Politics
Sports
Technology
Entertainment
Auto
Lifestyle
Inspirational
Career
Bengaluru
Delhi
Mumbai
Videos
Visual Stories
Reviews
Phone Reviews
Fitness Bands Reviews
Speakers Reviews
Find Cricket Statistics

More Links
  • Videos

Download Android App

Follow us on
  • Facebook
  • Twitter
  • Linkedin
  • Youtube
 
Home / News / India News / Government-owned BIBCOL to produce 2 crore COVAXIN doses every month
India

Government-owned BIBCOL to produce 2 crore COVAXIN doses every month

Government-owned BIBCOL to produce 2 crore COVAXIN doses every month
Written by Ramya Patelkhana
May 12, 2021, 07:45 pm 3 min read
Government-owned BIBCOL to produce 2 crore COVAXIN doses every month
Credits:
Centre gives nod for COVAXIN production at BIBCOL

To accelerate the production of COVAXIN—the indigenous COVID-19 vaccine developed by Hyderabad-based Bharat Biotech—amid severe vaccine shortage in India, the Centre on Wednesday reportedly gave its nod for production of COVAXIN at government-owned Bharat Immunologicals & Biologicals Corporation Limited (BIBCOL) in Uttar Pradesh's Bulandshahr. BIBCOL would manufacture two crore doses of the vaccine every month; the production is expected to start soon. Here's more.

Details
MoU signed between Bharat Biotech and BIBCOL for production

A Memorandum of Understanding (MoU) was reportedly signed between Bharat Biotech and BIBCOL for the manufacturing of COVAXIN at the latter's Bulandshahr plant. The Union Health Ministry would also allocate Rs. 30 crore-worth financial aid for the production. BIBCOL would use its existing spare capacity to manufacture COVAXIN. It earlier said it has the capabilities for producing the vaccine according to the government's guidelines.

About
BIBCOL is a PSU set up back in 1989

BIBCOL is a public sector undertaking (PSU) of the Government of India and comes under the administrative control of the Science and Technology Ministry's Department of Biotechnology. It was set up in 1989 by the government for supplying polio vaccines for the country. Today, BIBCOL produces oral polio vaccines (OPVs), other immunizers, diarrhea management kits, dispersible zinc tablets, and iron-folic acid (IFA) tablets.

Information
Three government-owned institutes roped in to boost vaccine production

Under Mission COVID Suraksha, the Centre reportedly roped in three government-owned biopharmaceutical organizations—BIBCOL, Haffkine Biopharmaceutical Corporation (Mumbai), and Indian Immunologicals Limited (Hyderabad)—to boost COVAXIN production in India. Haffkine Biopharmaceutical Corporation was granted permission in April to produce COVAXIN on a transfer of technology basis.

COVAXIN production
Production of COVAXIN in India to increase significantly

The move is expected to increase the manufacturing of the indigenous COVAXIN in India significantly. The Centre earlier said COVAXIN's production capacity will be doubled by June and is likely to get to nearly 10 crore doses per month by September 2021. To note, Bharat Biotech manufactures around one crore doses of the vaccine every month, says an April 25 report by Hindustan Times.

Vaccination drive
COVAXIN, Covishield currently being used under vaccination drive

COVAXIN is one of the two vaccines currently being administered under India's vaccination drive. It's been developed by Bharat Biotech in partnership with the Indian Council of Medical Research (ICMR). The other vaccine in use is Covishield—developed by Oxford-AstraZeneca and manufactured by Pune-based Serum Institute of India. Russia's Sputnik V vaccine was also approved by India and is expected to be available by May-end.

Share this timeline
Facebook
Whatsapp
Twitter
Linkedin
Ramya Patelkhana
Ramya Patelkhana
Mail
Ramya Patelkhana is a senior editor at NewsBytes. She has nearly seven years of experience in digital journalism and has previously worked with India News and Authint Media. She has a Bachelor's degree in Journalism and Mass Communication from the IK Gujral Punjab Technical University, Kapurthala, and an advanced diploma in Media Studies from IPW, New Delhi.
Latest
Bulandshahr
Vaccine
Coronavirus
COVID-19
Bharat Biotech
Related
Latest
Sennheiser Momentum True Wireless 3 earbuds launched at Rs. 25,000
Sennheiser Momentum True Wireless 3 earbuds launched at Rs. 25,000 Technology
Anderson, Broad return as England announce Test squad versus NZ
Anderson, Broad return as England announce Test squad versus NZ Sports
IPL 2022, KKR vs LSG: KL Rahul elects to bat
IPL 2022, KKR vs LSG: KL Rahul elects to bat Sports
'Spiderhead' trailer: Suspense, treachery drive Chris Hemsworth-led thriller
'Spiderhead' trailer: Suspense, treachery drive Chris Hemsworth-led thriller Entertainment
Mushfiqur Rahim surpasses 5,000 career Test runs: Decoding the numbers
Mushfiqur Rahim surpasses 5,000 career Test runs: Decoding the numbers Sports
Bulandshahr
UP: Doctor's son kidnapped, murdered by employees he sacked
UP: Doctor's son kidnapped, murdered by employees he sacked India
UP: Woman brutally thrashed by husband in Bulandshahr, dies
UP: Woman brutally thrashed by husband in Bulandshahr, dies India
Bulandshahr: Eight-year-old found dead in home; mother accuses ex-husband
Bulandshahr: Eight-year-old found dead in home; mother accuses ex-husband India
UP: Man kills wife, two daughters over suspected illicit relations
UP: Man kills wife, two daughters over suspected illicit relations India
UP-topper, studying in US, dies in accident after alleged harassment
UP-topper, studying in US, dies in accident after alleged harassment India
More News
Vaccine
COVID-19: India logs 2,487 fresh cases, 13 more fatalities
COVID-19: India logs 2,487 fresh cases, 13 more fatalities India
COVID-19: India logs 2,858 fresh cases, 11 more fatalities
COVID-19: India logs 2,858 fresh cases, 11 more fatalities India
India: Phase-2 trials of world's first one-shot pneumococcal vaccine soon
India: Phase-2 trials of world's first one-shot pneumococcal vaccine soon India
India inching closer to launching its first dengue vaccine
India inching closer to launching its first dengue vaccine India
National Vaccination Day 2022: Know theme, history, significance
National Vaccination Day 2022: Know theme, history, significance Lifestyle
More News
Coronavirus
COVID-19: India logs 3,303 new cases; 39 more deaths
COVID-19: India logs 3,303 new cases; 39 more deaths India
COVID-19 XE variant reported by Gujarat; detected in 67-year-old man
COVID-19 XE variant reported by Gujarat; detected in 67-year-old man India
COVID-19 vaccine precautionary dose available for 18+ from April 10
COVID-19 vaccine precautionary dose available for 18+ from April 10 India
COVID-19 survivors at risk of developing serious blood clots: Study
COVID-19 survivors at risk of developing serious blood clots: Study Technology
COVID-19: India reports 1,660 new cases, 4,100 more deaths
COVID-19: India reports 1,660 new cases, 4,100 more deaths India
More News
COVID-19
COVID-19: India reports 1,829 new cases, 33 more fatalities
COVID-19: India reports 1,829 new cases, 33 more fatalities India
COVID-19: India reports 1,569 new cases, 19 more deaths
COVID-19: India reports 1,569 new cases, 19 more deaths India
COVID-19: India logs 2,202 new cases; 27 more deaths
COVID-19: India logs 2,202 new cases; 27 more deaths India
North Korea: 8,20,620 fresh COVID-19 cases in just 3 days
North Korea: 8,20,620 fresh COVID-19 cases in just 3 days World
North Korea reports 6 COVID-19 deaths, isolates 1,87,800 people
North Korea reports 6 COVID-19 deaths, isolates 1,87,800 people World
More News
Bharat Biotech
Centre denies asking Bharat Biotech to address WHO's COVAXIN suspension
Centre denies asking Bharat Biotech to address WHO's COVAXIN suspension India
COVAXIN likely to get approval for children above 2yrs: Report
COVAXIN likely to get approval for children above 2yrs: Report India
COVAXIN supply to be increased as teens get COVID-19 vaccines
COVAXIN supply to be increased as teens get COVID-19 vaccines India
Are Indian vaccines effective against Omicron? Here's what manufacturers say
Are Indian vaccines effective against Omicron? Here's what manufacturers say India
COVAXIN gets WHO approval for emergency use listing
COVAXIN gets WHO approval for emergency use listing India
More News
Related
Biological E-manufactured J&J's single-dose COVID-19 vaccine in India by October
Biological E-manufactured J&J's single-dose COVID-19 vaccine in India by October India
Expert panel recommends emergency use authorization for Zydus's three-dose vaccine
Expert panel recommends emergency use authorization for Zydus's three-dose vaccine India
Government expert panel recommends conducting trials on mixing Covishield, COVAXIN
Government expert panel recommends conducting trials on mixing Covishield, COVAXIN India
Next News Article
Next News Article

Love India news?

Subscribe to stay updated.

India Thumbnail
India News Business News World News Politics News Sports News Technology News Entertainment News Auto News Lifestyle News Inspirational News
Career News Bengaluru News Delhi News Mumbai News Mukesh Ambani Indian Premier League (IPL) Karnataka Samsung Xiaomi West Bengal
Bihar Virat Kohli Rohit Sharma Haryana Narendra Modi Arvind Kejriwal Tamil Nadu Gujarat Yogi Adityanath YouTube
Instagram Hollywood News Uttar Pradesh Kerala Netflix Bollywood News Mamata Banerjee Maruti Suzuki Rahul Gandhi Elon Musk
Shah Rukh Khan Chelsea FC OPPO Akhilesh Yadav Indian Cricket Team Apple Manchester United Salman Khan Cryptocurrency OnePlus
Amitabh Bachchan ICC Women's World Cup Vivo India vs Sri Lanka
About Us Privacy Policy Terms & Conditions Contact Us Ethical Conduct Grievance Redressal News News Archive Topics Archive IPL 2022 Schedule IPL 2022 Points Table Find Cricket Statistics
Follow us on
Facebook Twitter Linkedin Youtube
All rights reserved © NewsBytes 2022